Literature DB >> 27777356

Prolonged Baroreflex Activation Abolishes Salt-Induced Hypertension After Reductions in Kidney Mass.

Drew A Hildebrandt1, Eric D Irwin1, Thomas E Lohmeier2.   

Abstract

Chronic electric activation of the carotid baroreflex produces sustained reductions in sympathetic activity and arterial pressure and is currently being evaluated for therapy in patients with resistant hypertension. However, patients with significant impairment of renal function have been largely excluded from clinical trials. Thus, there is little information on blood pressure and renal responses to baroreflex activation in subjects with advanced chronic kidney disease, which is common in resistant hypertension. Changes in arterial pressure and glomerular filtration rate were determined in 5 dogs after combined unilateral nephrectomy and surgical excision of the poles of the remaining kidney to produce ≈70% reduction in renal mass. After control measurements, sodium intake was increased from ≈45 to 450 mol/d. While maintained on high salt, animals experienced increases in mean arterial pressure from 102±4 to 121±6 mm Hg and glomerular filtration rate from 40±2 to 45±2 mL/min. During 7 days of baroreflex activation, the hypertension induced by high salt was abolished (103±6 mm Hg) along with striking suppression of plasma norepinephrine concentration from 139±21 to 81±9 pg/mL, but despite pronounced blood pressure lowering, there were no significant changes in glomerular filtration rate (43±2 mL/min). All variables returned to prestimulation values during a recovery period. These findings indicate that after appreciable nephron loss, chronic suppression of central sympathetic outflow by baroreflex activation abolishes hypertension induced by high salt intake. The sustained antihypertensive effects of baroreflex activation occur without significantly compromising glomerular filtration rate in remnant nephrons.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  baroreflex; blood pressure; glomerular filtration rate; hypertension; sympathetic nervous system

Mesh:

Substances:

Year:  2016        PMID: 27777356      PMCID: PMC5159250          DOI: 10.1161/HYPERTENSIONAHA.116.08293

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  49 in total

Review 1.  Hyperfiltration and glomerulosclerosis.

Authors:  Thomas H Hostetter
Journal:  Semin Nephrol       Date:  2003-03       Impact factor: 5.299

2.  Systemic and renal-specific sympathoinhibition in obesity hypertension.

Authors:  Thomas E Lohmeier; Radu Iliescu; Boshen Liu; Jeffrey R Henegar; Christine Maric-Bilkan; Eric D Irwin
Journal:  Hypertension       Date:  2011-12-19       Impact factor: 10.190

3.  Prognostic significance of a reduced glomerular filtration rate and interaction with microalbuminuria in resistant hypertension: a cohort study.

Authors:  Gil F Salles; Claudia R L Cardoso; Vinicius S Pereira; Roberto Fiszman; Elizabeth S Muxfeldt
Journal:  J Hypertens       Date:  2011-10       Impact factor: 4.844

4.  Renal responses to chronic suppression of central sympathetic outflow.

Authors:  Radu Iliescu; Eric D Irwin; Dimitrios Georgakopoulos; Thomas E Lohmeier
Journal:  Hypertension       Date:  2012-07-02       Impact factor: 10.190

5.  Renal responses to long-term carotid baroreflex activation therapy in patients with drug-resistant hypertension.

Authors:  Teba Alnima; Peter W de Leeuw; Frans E S Tan; Abraham A Kroon
Journal:  Hypertension       Date:  2013-04-15       Impact factor: 10.190

Review 6.  Pathophysiology of hypertensive renal damage: implications for therapy.

Authors:  Anil K Bidani; Karen A Griffin
Journal:  Hypertension       Date:  2004-09-27       Impact factor: 10.190

Review 7.  Renal denervation for the treatment of resistant hypertension: review and clinical perspective.

Authors:  Radu Iliescu; Thomas E Lohmeier; Ionut Tudorancea; Luke Laffin; George L Bakris
Journal:  Am J Physiol Renal Physiol       Date:  2015-07-29

8.  Prolonged activation of the baroreflex produces sustained hypotension.

Authors:  Thomas E Lohmeier; Eric D Irwin; Martin A Rossing; David J Serdar; Robert S Kieval
Journal:  Hypertension       Date:  2004-01-05       Impact factor: 10.190

Review 9.  The double challenge of resistant hypertension and chronic kidney disease.

Authors:  Patrick Rossignol; Ziad A Massy; Michel Azizi; George Bakris; Eberhard Ritz; Adrian Covic; David Goldsmith; Gunnar H Heine; Kitty J Jager; Mehmet Kanbay; Francesca Mallamaci; Alberto Ortiz; Raymond Vanholder; Andrzej Wiecek; Carmine Zoccali; Gérard Michel London; Bénédicte Stengel; Denis Fouque
Journal:  Lancet       Date:  2015-10-17       Impact factor: 79.321

Review 10.  Cardiovascular and renal complications in patients with resistant hypertension.

Authors:  Elizabeth S Muxfeldt; Fabio de Souza; Victor S Margallo; Gil F Salles
Journal:  Curr Hypertens Rep       Date:  2014-09       Impact factor: 5.369

View more
  9 in total

1.  Effect of baroreflex activation therapy on renal sodium excretion in patients with resistant hypertension.

Authors:  Mark Lipphardt; Michael J Koziolek; Luca-Yves Lehnig; Ann-Kathrin Schäfer; Gerhard A Müller; Stephan Lüders; Manuel Wallbach
Journal:  Clin Res Cardiol       Date:  2019-04-06       Impact factor: 5.460

Review 2.  [Baroreflex activation therapy : Indication and evidence in resistant hypertension and heart failure].

Authors:  M Wallbach; M J Koziolek; R Wachter
Journal:  Internist (Berl)       Date:  2018-10       Impact factor: 0.743

Review 3.  Sensory signals mediating high blood pressure via sympathetic activation: role of adipose afferent reflex.

Authors:  Carolina Dalmasso; Jacqueline R Leachman; Jeffrey L Osborn; Analia S Loria
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2019-12-23       Impact factor: 3.619

4.  [Baroreceptor activation therapy for therapy-resistant hypertension: indications and patient selection : Recommendations of the BAT consensus group 2017].

Authors:  M Koziolek; J Beige; M Wallbach; D Zenker; G Henning; M Halbach; N Mader; F Mahfoud; G Schlieper; V Schwenger; M Hausberg; J Börgel; M Lodde; M van der Giet; J Müller-Ehmsen; J Passauer; S Parmentier; S Lüders; B K Krämer; S Büttner; F Limbourg; J Jordan; O Vonend; H-G Predel; H Reuter
Journal:  Internist (Berl)       Date:  2017-10       Impact factor: 0.743

5.  Estrogen-dependent depressor response of melatonin via baroreflex afferent function and intensification of PKC-mediated Nav1.9 activation.

Authors:  Di Wu; Dan Zhao; Di Huang; Xun Sun; Ke-Xin Li; Yan Feng; Qiu-Xin Yan; Xin-Yu Li; Chang-Peng Cui; Hu-Die Li; Bai-Yan Li
Journal:  Acta Pharmacol Sin       Date:  2022-02-07       Impact factor: 7.169

6.  Excessive dietary salt promotes aortic stiffness in murine renovascular hypertension.

Authors:  Leon J DeLalio; Scott Hahn; Pedro L Katayama; Megan M Wenner; William B Farquhar; Adam C Straub; Sean D Stocker
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-04-17       Impact factor: 4.733

7.  In silico trial of baroreflex activation therapy for the treatment of obesity-induced hypertension.

Authors:  John S Clemmer; W Andrew Pruett; Robert L Hester
Journal:  PLoS One       Date:  2021-11-18       Impact factor: 3.240

8.  Endothelin B receptors impair baroreflex function and increase blood pressure variability during high salt diet.

Authors:  Bryan K Becker; Jermaine G Johnston; Carolyn M Young; Alfredo A Torres Rodriguez; Chunhua Jin; David M Pollock
Journal:  Auton Neurosci       Date:  2021-03-11       Impact factor: 3.145

9.  Reduced Renal Mass, Salt-Sensitive Hypertension Is Resistant to Renal Denervation.

Authors:  Ionut Tudorancea; Thomas E Lohmeier; Barbara T Alexander; Dragos Pieptu; Dragomir N Serban; Radu Iliescu
Journal:  Front Physiol       Date:  2018-04-30       Impact factor: 4.566

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.